11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A distant trophoblast-specific enhancer controls HLA-G expression at the maternal–fetal interface

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Successful pregnancy poses an immunological paradox, as the mother’s immune system does not reject a fetus, even though it is a partially foreign tissue. Fetal extravillous trophoblasts (EVTs) deeply invade the uterus and interact with maternal immune cells without facing rejection. The nonclassical major histocompatibility complex (MHC) molecule HLA-G is essential for immune tolerance induction in pregnancy, yet the mechanism by which EVTs uniquely express HLA-G remains unknown. Using high-throughput cis-regulatory element dissection and genome editing tools, we discovered a remote enhancer essential for HLA-G expression in human EVTs, describing the basis for its selective expression at the maternal–fetal interface. These findings provide insight into immune tolerance induction during pregnancy and may yield new therapeutic targets for pregnancy-related disorders.

          Abstract

          HLA-G, a nonclassical HLA molecule uniquely expressed in the placenta, is a central component of fetus-induced immune tolerance during pregnancy. The tissue-specific expression of HLA-G, however, remains poorly understood. Here, systematic interrogation of the HLA-G locus using massively parallel reporter assay (MPRA) uncovered a previously unidentified cis-regulatory element 12 kb upstream of HLA-G with enhancer activity, Enhancer L. Strikingly, clustered regularly-interspaced short palindromic repeats (CRISPR)/Cas9-mediated deletion of this enhancer resulted in ablation of HLA-G expression in JEG3 cells and in primary human trophoblasts isolated from placenta. RNA-seq analysis demonstrated that Enhancer L specifically controls HLA-G expression. Moreover, DNase-seq and chromatin conformation capture (3C) defined Enhancer L as a cell type-specific enhancer that loops into the HLA-G promoter. Interestingly, MPRA-based saturation mutagenesis of Enhancer L identified motifs for transcription factors of the CEBP and GATA families essential for placentation. These factors associate with Enhancer L and regulate HLA-G expression. Our findings identify long-range chromatin looping mediated by core trophoblast transcription factors as the mechanism controlling tissue-specific HLA-G expression at the maternal–fetal interface. More broadly, these results establish the combination of MPRA and CRISPR/Cas9 deletion as a powerful strategy to investigate human immune gene regulation.

          Related collections

          Author and article information

          Journal
          Proc Natl Acad Sci U S A
          Proc. Natl. Acad. Sci. U.S.A
          pnas
          pnas
          PNAS
          Proceedings of the National Academy of Sciences of the United States of America
          National Academy of Sciences
          0027-8424
          1091-6490
          10 May 2016
          13 April 2016
          : 113
          : 19
          : 5364-5369
          Affiliations
          [1] aDepartment of Stem Cell and Regenerative Biology, Harvard University , Cambridge, MA 02138;
          [2] bDepartment of Molecular and Cellular Biology, Harvard University , Cambridge, MA 02138;
          [3] cThe Broad Institute of Massachusetts Institute of Technology and Harvard , Cambridge, MA 02142;
          [4] dHarvard Stem Cell Institute, Harvard University , Cambridge, MA 02138;
          [5] eDivision of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School , Boston, MA 02115;
          [6] fComputer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology , Cambridge, MA 02139;
          [7] gDepartment of Pathology, Beth Israel Deaconess Medical Center , Boston, MA 02156
          Author notes
          1To whom correspondence may be addressed. Email: leonardoferreira@ 123456fas.harvard.edu or jlstrom@ 123456fas.harvard.edu .

          Contributed by Jack L. Strominger, February 23, 2016 (sent for review February 5, 2016; reviewed by Koichi S. Kobayashi, Peter Parham, and Peter J. van den Elsen)

          Author contributions: L.M.R.F., T.B.M., R.C., J.L.R., C.A.C., and J.L.S. designed research; L.M.R.F., T.B.M., T.S.M., W.M., C.W.O., H.A.B.G., R.C., and R.I.S. performed research; L.M.R.F., T.S.M., W.M., C.W.O., R.I.S., and D.K.G. contributed new reagents/analytic tools; L.M.R.F., T.B.M., T.T., H.A.B.G., R.C., D.K.G., J.L.R., C.A.C., and J.L.S. analyzed data; and L.M.R.F., T.B.M., and J.L.S. wrote the paper.

          Reviewers: K.S.K., College of Medicine, Texas A&M Health Science Center; P.P., Stanford University School of Medicine; and P.J.v.d.E., Leiden University Medical Center.

          Article
          PMC4868469 PMC4868469 4868469 201602886
          10.1073/pnas.1602886113
          4868469
          27078102
          6d8997a8-9206-4f67-944e-4a1e87395e1a
          History
          Page count
          Pages: 6
          Funding
          Funded by: HHS | NIH | National Human Genome Research Institute (NHGRI) 100000051
          Award ID: R01HG006785
          Funded by: Human Frontier Science Program (HFSP) 501100000854
          Award ID: 1K01DK101684-01
          Funded by: HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) 100000050
          Award ID: U01HL100408
          Funded by: HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI) 100000050
          Award ID: U01HL10744
          Funded by: HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 100000062
          Award ID: R01DK097768
          Funded by: HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 100000062
          Award ID: R01DK072041
          Funded by: Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) 100006492
          Award ID: AI053330
          Categories
          Biological Sciences
          Immunology and Inflammation

          CRISPR/Cas9,human immune gene regulation,pregnancy,immune tolerance,MPRA

          Comments

          Comment on this article